PHBI · Pharmagreen Biotech Inc. · Debt
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt upon the Company's ability to continue as a going concern. These consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.”View the 10-Q filed Aug 14, 2023
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Convertible debt, including current maturities | 2023-06-30 | USD 24,150 | 10-Q filed 2023-08-14 |
| Convertible notes payable, including current maturities | 2023-06-30 | USD 27,068 | 10-Q filed 2023-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Loans payable, including current maturities | 2023-06-30 | USD 129,266 | 10-Q filed 2023-08-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.